Compared to the pivotal SCHOLAR-1 study by Crump and colleagues (see link), our results show lower overall survival rates, emphasizing the disparity between clinical trials and real-world practice! [6/8] #lymsm https://t.co/uVJ7O9rR4g
RT @DrRaulCordoba: #OncoAlert #lymsm Outcomes in refractory diffuse large B-cell #lymphoma: results from the international SCHOLAR-1 study…
#OncoAlert #lymsm Outcomes in refractory diffuse large B-cell #lymphoma: results from the international SCHOLAR-1 study https://t.co/4QOMc2UV5S
@oncology_bg This is somehow missing the point... Rates of CR is this population are < 10%, median survival ~ 6 months. https://t.co/cifAH29ocT The point the authors are trying to make is that depth of response seems to impact DOR. Agree that their …